天星医疗拟港股上市 中国证监会要求补充说明主要股东上层投资人等情况

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 11 companies, including Tianxing Medical, which is preparing for an IPO on the Hong Kong Stock Exchange. The CSRC has requested detailed clarifications on various aspects of the company's operations and shareholder structure [1][2]. Group 1: Company Information - Tianxing Medical is required to provide information about its major shareholders, specifically regarding the status of "overseas enterprises" and "Hong Kong companies" among its upper-level investors, including any legal restrictions on shareholding [1]. - The company must clarify the progress of state-owned shareholders in fulfilling state-owned share identification and other state asset management procedures [1]. - Tianxing Medical needs to explain its specific business types, operational methods, and future plans in simple terms, particularly regarding its AI rehabilitation products and whether it holds the necessary qualifications [1][2]. Group 2: Financial Performance - For the fiscal years 2022 to 2025 (up to May 31), Tianxing Medical reported revenues of approximately 147 million, 239 million, 327 million, and 111 million RMB, respectively. The net profits for the same periods were approximately 40.34 million, 57.11 million, 95.39 million, and 32.59 million RMB [3]. Group 3: Regulatory Compliance - The company must disclose the specifics of its previous IPO application to the Shanghai Stock Exchange, including reasons for withdrawal and plans for future A-share listings [2]. - Tianxing Medical is required to clarify the operational status of its subsidiaries in relation to medical device internet information services, including necessary qualifications and compliance with foreign investment regulations [2]. - The company must provide details on its business dealings with DSM Biomedical, including potential legal disputes and their implications for the IPO [2]. Group 4: Shareholder Agreements - Tianxing Medical needs to explain the reasons behind a waiver agreement signed by two shareholders in January 2021, which resulted in a change of control, and whether there are any shareholding proxy arrangements [2]. - The company must confirm whether the shares held by shareholders participating in the "full circulation" are subject to any pledges, freezes, or other rights defects [3].